28 min listen
How ‘New Science’ Is Changing Healthcare
FromBuilt for Change
ratings:
Length:
29 minutes
Released:
Oct 13, 2021
Format:
Podcast episode
Description
If there’s one good thing that’s come from the pandemic, it’s this: Scientists and drug manufacturers came together in record time and with a shared purpose to create a safe and effective Covid-19 vaccine. In doing so, they set a precedent for medical advancements. So, where do we go from here? In this episode, we’ll talk about how biopharma companies can learn from last year’s disruption and harness what Accenture calls ‘New Science’ to rapidly discover and deliver revolutionary treatments and preparing for in the midst of regulatory and economic shifts. We’ll speak with Chris Gibson, C.E.O. and Co-Founder at Recursion; Stuart Henderson, Global Industry Lead — Life Sciences at Accenture; and David Coman, C.E.O at Science 37.This week's guests: Chris Gibson, C.E.O. and Co-Founder at RecursionStuart Henderson, Global Industry Lead — Life Sciences at AccentureDavid Coman, C.E.O at Science 37
Released:
Oct 13, 2021
Format:
Podcast episode
Titles in the series (40)
Why Business Leaders Must Become Tech Leaders: Until 2020, many companies believed they were further along in their digital evolution than they actually were. The pandemic revealed the truth about that technology gap — and also the immense opportunity it presents for organizations willing to change. In this conversation with Dr. Mona Flores, head of medical A.I. at NVIDIA; Port of Rotterdam C.E.O. Allard Castelein and Accenture’s C.T.O. Paul Daugherty, we learn how some enterprises reimagined their systems to leverage technology, say good-bye to ‘the way we’ve always done things’ and meet the needs of the moment. The leaders who master change embody the trends outlined in Accenture’s Technology Vision 2021 report. by Built for Change